pSivida initiates Phase IIb pancreatic cancer trial

The first patient has received treatment at Guy’s and St Thomas’s NHS Foundation Trust in London. A total of six patients will be entered into this trial at two centers in the UK. The study will determine the safety of escalating radiation doses of the BrachySil device, with tumor response as a secondary end point.

pSivida’s BrachySil is an oncology product which comprises a combination of BioSilicon, a porous silicon, and the isotope 32Phosphorus, an anti-cancer therapeutic.

Paul Ashton, managing director of pSivida, said: “We are very pleased to be able to progress BrachySil as a potential treatment for this terrible disease as we move one step closer to approval.”